GlassScriptPhysician profile
Cindy V Johnston
NPI 1932332384
$27,012.89
in general payments reported to CMS, 2019-2025
37 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,205 · 2020: $2,289 · 2021: $892 · 2022: $2,206 · 2023: $2,914 · 2024: $4,001 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $5,413 · Travel and Lodging: $1,070 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,706.35 |
| Consulting Fee | $5,412.50 |
| Travel and Lodging | $1,070.34 |
| Education | $231.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,895.26 | 2019-2025 | |
| Abbvie INC. | $3,686.24 | 2019-2025 | |
| Janssen Biotech, INC. | $3,279.67 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $1,471.68 | 2019-2025 | Krystexxa, Evenity, Tavneos |
| Ucb, INC. | $1,081.24 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,064.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,061.71 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $955.83 | 2019-2025 | Taltz, Zepbound |
| Janssen Scientific Affairs, LLC | $822.83 | 2019-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $730.45 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $457.69 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $431.51 | 2021-2025 | Lupkynis |
| Genzyme Corporation | $404.61 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.51 | 2019-2025 | Spevigo |
| Horizon Therapeutics Plc | $262.23 | 2019-2023 | Krystexxa |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.